



सत्यमेव जयते

Department of Pharmaceuticals
Government of India



INDIA PHARMA 2019

4th International Conference on Pharmaceuticals Industry
18th – 19th February 2019, Hotel Lalit Ashok, Bengaluru, India

Theme: Enabling Affordable Quality Healthcare

Draft Conference Program

DATE / TIME	EVENT	
DAY 1, 18th February 2018		
0930-1120	Inaugural Session and Awards Ceremony: India Pharma 2019 & India Medical Device 2019	
	0830-0930	Registration
	0930-1120	Inaugural Session
1120-1135	Media Interaction with Hon'ble Minister for Chemicals & Fertilizers, Ministry of Chemicals & Fertilizers. Govt. of India	
1135-1200	Tea/Coffee Break	
1200-1400	INDIA PHARMA CEO's Roundtable with Hon'ble Minister for Chemicals & Fertilizers, Ministry of Chemicals & Fertilizers. Govt. of India (By Invitation only)	
1200-1330 (Parallel)	Conference Session: Promoting Innovation Ecosystem in India for Pharmaceuticals Industry	
	<p>Session brief: The Indian pharmaceutical industry is recognized as a global leader in the production of high-quality generic drugs and is ranked third in terms of manufacturing pharmaceutical products by volume. Alongside, India drug manufacturers have also steadily developed a healthy pipeline of New Chemical Entities (NCEs) backed by laudable initiatives by BIRAC, CSIR, and DBT. This session aims to take stalk of innovative ecosystem in the pharmaceutical industry in India and discuss latest developments and technologies that will catalyse drug development. It will also discuss any policy initiatives required to further strengthen industry and academia collaboration to strengthen new drug discovery.</p> <p>Chair: Shri Rajneesh Tingal, Joint Secretary, Department of Pharmaceuticals, GoI*</p> <p>Co-chair: Dr. Shekhar Mande, Director General of Council of Scientific and Industrial Research (CSIR) and Secretary of the Department of Scientific and Industrial Research (DSIR)</p> <p>Moderator: TBD</p> <p>Panellists:</p> <ol style="list-style-type: none"> 1. Pfizer 2. Abbott 3. Zydus 4. Sun Pharma 5. Novartis 6. NIPER Mohali <p>Expected Participation: Officials from Govt. of India, Clinical research organizations, Industry participants, Regulators – state regulators and DCG, Academia, Trade and Business officials from Embassies / Foreign missions</p> <p style="text-align: right;"><i>(Seating plan: Dais and Theatre style)</i></p>	

<p>1330-1430 1400-1430</p>	<p>Lunch for Delegates Lunch for CEOs/Dignitaries</p>
<p>1430-1630</p>	<p>Conference Session: Enhancing cross-border trade: Discussing Import and Export related opportunities and challenges for Indian Pharmaceutical Industry</p>
	<p>Session brief: For India, US is one of the largest importers of pharma products while India imports majority of raw materials and intermediates from China. Increasing protectionist measures and pricing concerns in the global markets tend to put a lot of pressure on India companies with respect to market access and business viability. In light of current global trade scenario, it is important to discuss how to optimize import and export portfolio for Indian pharmaceutical companies to reduce risk exposure. In this session, we strategically look at markets such as China, Vietnam, CIS Countries, Saudi Arabia and LATAM to identify import and export opportunities for APIs/ intermediates as well as finished dosage formulations.</p> <p>Format of the session:</p> <ul style="list-style-type: none"> • Industry representative to make a presentation on target geographies (10 min each) covering aspects such as <ul style="list-style-type: none"> ○ Market Landscape of target geographies ○ API Import opportunities from target geographies and registration requirements for sale of export products ○ Best business practices for marketing and distribution (Franchisee model vs. ownership model) ○ Taxation, Profit Repatriation & Incentives (if any) provided by foreign government to Indian investors • Presentation by WHO on findings of Survey of Indian Pharma Enterprises and presenting next steps <p>Chair: Shri Alok Vardhan Chaturvedi, Director General, DGFT* Co-Chair: Shri Shyamal Misra, Joint Secretary, Ministry of Commerce, GoI* Moderator: Dr Dinesh Dua, Chairman, Pharmexcil*</p> <p>Panellists:</p> <ol style="list-style-type: none"> 1. Mr Ravi Uday Bhaskar, DG, Pharmexcil 2. Representatives from Drug Regulators of target geographies 3. Representative from WHO 4. Representatives from Glenmark Pharmaceuticals Ltd., Lupin Ltd, Alembic, Dr. Reddy's, Cipla, Sun Pharma <p>Session Format: Industry representative to make a presentation (10-15 min duration) on the enlisted geographies to put into perspective the pharma export opportunities to these regions. Post the presentations, the session will open for a Q&A session with regulators from China, Vietnam, CIS Countries, Saudi Arabia and LATAM.</p> <p>Expected Participation: Officials from Govt. of India, Industry Members, Contract Manufacturing Organizations, Trade and Business officials from Embassies / Foreign missions</p> <p style="text-align: right;">(Seating plan: Dais and Theatre style)</p>
<p>1630-1645</p>	<p>Tea Break</p>

1645-1745	Industry interaction with State Drug Controllers and CDSCO for harmonization of regulatory requirements
1745-1800	Tea Break
1800-1930	JOINT CLOSED-DOOR SESSION: INTERNATIONAL REGULATORS INTERACTION WITH CEO'S OF PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRY (By Invitation Only)
	<p>Session Brief: The session aims to provide a platform for Pharmaceutical and Med-tech CEOs to place their views on evolving international regulatory scenario. This is to enable Indian manufacturers faster access to international markets while at the same time allow international markets to harness the growth and export potential of Indian manufacturers.</p>
1930 onwards	Networking Dinner Hosted by Department of Pharmaceuticals, Govt. of India

DAY 2, 19th February 2019

1000-1130	Technical Workshop by WHO
1130-1145	Tea Break
1145-1300	Joint Session: Decoding applications of Artificial Intelligence in Pharmaceutical and Medical Devices Industry
	<p>Session brief: Machine learning, and artificial intelligence have become widely discussed topics in the area of life sciences and healthcare over the last several years. While a lot of pharmaceutical companies, med-tech and healthcare organizations express considerable interest in possible new opportunities, associated with the use of artificial intelligence for early drug discovery, clinical trials optimization, and business intelligence. The use of Artificial Intelligence (AI) in the pharmaceutical industry is envisioned from innovation stage to supply chain management. The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines. AI has the potential to transform the drug development process making it both more efficient and more effective, thus benefiting all parties involved—from the companies developing new drugs to the patients in desperate need of viable treatments. In terms of supply chain optimization and inventory management, the use of AI tools allows companies to gather data about inventory distribution practices and availability for every SKU to enable accurate forecasting and analytics for more efficient production and distribution. However, a considerable gap still exists when it comes to understanding new technologies and its true potential by pharmaceutical and med-tech professionals and leaders.</p> <p>Key Points of Discussion</p> <ol style="list-style-type: none"> 1. Use of AI in drug discovery – generating novel drug candidates, understanding disease mechanisms, analysing pre-clinical data etc. 2. Case studies on how deployment on AI tools are helping companies improve quality in manufacturing. 3. Case studies on impact of AI tools and analytics on forecasting and analytics to improve drug distribution and supply chain

	<p>Chair: Ms Anna Roy, Adviser, NITI Aayog Moderator: Senior Consultant, Knowledge Partner Panellists:</p> <ul style="list-style-type: none"> • Dr. Vivek Ahuja, Head Pharmacovigilance, Sun Pharma • Speaker from Novartis • Speaker from GSK • Speaker from Pfizer • Speaker from Indigene/ Intuition Systems • Speaker from Intel/ IBM <p>Who will attend: The session will be for future focused technology leaders. This unconventional session is designed to discuss the current innovations and technology trends in the Pharma and Med-Tech industry. From presentations to discussions, to latest industry insights, participants will discuss and experience the latest innovations in the pharmaceutical and med-tech sector, and further have deliberations upon the same.</p>
1300-1400	Lunch Break
1400-1530	Promoting Growth of Biologicals Sector in India by Enabling Quality in Manufacturing Standards and Ease of Market Access
	<p>Session brief: The Indian biosimilar market is poised for high growth augured by the launch of new products. Indian life science firms are investing in biosimilar development to acquire skill sets, latest manufacturing technologies and to be able to succeed in the complex regulatory environment globally. The session aims to discuss:</p> <ol style="list-style-type: none"> 1. Status of the biosimilars market in India. Highlighting success stories of the sector in both domestic as well as global markets 2. Regulatory requirements for marketing authorization of similar biologics in India. 3. The role of CDSCO and National Institute of Biologicals (NIB) in ensuring provision of quality biological drugs and development and validating standards for quality control testing of biologicals. <p>Session Chair: Dr S Eswara Reddy, Drug Controller General of India (DCGI), Central Drugs Standard Control Organization, MoH&FW, Govt. of India*</p> <p>Session Co-chair: Dr. Surinder Singh, Director, National Institute of Biologicals*</p> <p>Session Moderated by: Dr. Bobby George, VP & Head Regulatory Affairs, Reliance Life Sciences*</p> <p>Session Constituents:</p> <ol style="list-style-type: none"> 1. Ms. Mahima Datla, Managing Director, Biological E. Limited* 2. Dr Davinder Gill, CEO, Hilleman Laboratories Ltd* 3. Dr. Sanjeev Kumar, President, Zydus Cadila* 4. Pfizer 5. Mylan 6. Roche 7. MSD

	<p>Expected Participation: Officials from Govt. of India, Industry Members, Contract Manufacturing Organizations, Trade and Business officials from Embassies / Foreign missions</p> <p style="text-align: right;"><i>(Seating plan: Dais and Theatre style)</i></p>
1530-1545	Tea Break
1545-1700	Joint Session: Pharmaceuticals and Med- Tech: Gearing up for Ayushman Bharat
	<p>Session Brief:</p> <p><u>Track 1: The session would revolve around Ayushman Bharat, and how the entire ecosystem can move together towards Universal Healthcare.</u></p> <ul style="list-style-type: none"> • Role of Medical Technology & Pharmaceutical Industry • Learnings from AB-PMJAY and road ahead for gearing up to serve a population of 500 Million. • Role to be played by med tech and pharma sector in skilling and capacity building of healthcare professionals, doctors, physicians, nurses, technicians etc. and institutionalizing this initiative for constant up-skilling of capabilities in the healthcare system • Steps towards a more inclusive Universal Healthcare coverage—International best practices <p><u>Track 2: Enabling Med-Tech & Pharmaceuticals to Efficiently Serve Ayushman Bharat</u> Ayushman Bharat’s roll out makes a promising start to expand the market size and fill the longstanding demand side gaps in the medical device industry. The next BIG question arises on the supply side preparedness to meet this rising demand. In this evolving backdrop, this session aims at deliberating the short/medium/ long term structural/ operational changes required to enable this industry to serve this most aspirational health scheme rolled out by Gol.</p> <p>Chair: Dr Indu Bhushan, CEO - National Health Agency, Government of India Moderator: Dr Alok Roy, Co-Chair – FICCI Health Services Committee; Chairman, Medica Hospitals</p> <p>Panellists:</p> <p><u>Government Officials:</u></p> <ul style="list-style-type: none"> • Ms Shubhra Singh, Chairman, NPPA • Mr Manoj Jhalani, Additional Secretary, Ministry of Health & Family Welfare, Government of India • Ms NT Abroo, Executive Director - Vajpayee Aarogyasree <p><u>Industry</u></p> <ul style="list-style-type: none"> • Mr S Sridhar, Managing Director, Pfizer India Ltd • Mr Badhri Iyenger, Chair - FICCI Medical Device Committee; Managing Director - South Asia & South East Asia, Smith & Nephew Healthcare Ltd. • Mr Sanjay Bhutani, Managing Director – India & SAARC, Bausch & Lomb • Mr Kaustav Banerjee, Managing Director, Zimmer Biomet <p style="text-align: right;"><i>(Seating plan: Dais and Theatre style)</i></p>
1700	Close